SCHEMBL15418352

SCHEMBL15418352

CC(C)(OCCN1CCCC1)c1ccc(N)c(C2=CCCCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPIN1 Q9Y657 1/20 0.43
PTPN11 Q06124 1/20 0.38
HRH3 Q9Y5N1 4/20 0.37
KCNH2 Q12809 3/20 0.37
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD1 P21728 1/20 0.34
TBXA2R P21731 1/20 0.34
ACHE P22303 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15418350 0.85 SPIN1 (0.39) SPIN1PTPN11HRH3KCNH2ALDH1A1
SCHEMBL15738540 0.76 CSF1R (0.46) HRH3ALDH1A1ACHEKDM4E
SCHEMBL15418318 0.72 HRH3 (0.43) SPIN1HRH3KCNH2ALDH1A1SMN1; SMN2
SCHEMBL14384827 0.72 CSF1R (0.45)
SCHEMBL2938391 0.65 KIT (0.44) SPIN1PTPN11KCNH2HTR1AFFAR2
SCHEMBL15418492 0.63 CSF1R (0.57) HRH3KCNH2ALDH1A1SMN1; SMN2CHRM2
SCHEMBL3083160 0.60 JAK2 (0.44) PTPN11FFAR2CYP1A2
SCHEMBL15738829 0.60 HRH3 (0.39) SPIN1HRH3CHRM2CHRM1
SCHEMBL3656499 0.58 CSF1R (0.37) PTPN11FFAR2
SCHEMBL824037 0.58 ALDH1A1 (0.50) HRH3KCNH2ALDH1A1SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK SPIN1 1274/4885PTPN11 142/4885HRH3 685/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK SPIN1 1274/4885PTPN11 142/4885HRH3 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.